BIOMAT Database Logo BIOMAT Database Logo

Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase: synthesis, structure-activity relationships, and pharmacokinetics. 2012

J Maina Ndungu, and Stefanie A Krumm, and Dan Yan, and Richard F Arrendale, and G Prabhakar Reddy, and Taylor Evers, and Randy Howard, and Michael G Natchus, and Manohar T Saindane, and Dennis C Liotta, and Richard K Plemper, and James P Snyder, and Aiming Sun
Emory Institute for Drug Discovery, Emory University, 1515 Dickey Drive, Atlanta, Georgia 30322, USA.

The measles virus (MeV), a member of the paramyxovirus family, is an important cause of pediatric morbidity and mortality worldwide. In an effort to provide therapeutic treatments for improved measles management, we previously identified a small, non-nucleoside organic inhibitor of the viral RNA-dependent RNA polymerase by means of high-throughput screening. Subsequent structure-activity relationship (SAR) studies around the corresponding pyrazole carboxamide scaffold led to the discovery of 2 (AS-136a), a first generation lead with low nanomolar potency against life MeV and attractive physical properties suitable for development. However, its poor water solubility and low oral bioavailability (F) in rat suggested that the lead could benefit from further SAR studies to improve the biophysical characteristics of the compound. Optimization of in vitro potency and aqueous solubility led to the discovery of 2o (ERDRP-00519), a potent inhibitor of MeV (EC(50) = 60 nM) with an aqueous solubility of approximately 60 μg/mL. The agent shows a 10-fold exposure (AUC/C(max)) increase in the rat model relative to 2, displays near dose proportionality in the range of 10-50 mg/kg, and exhibits good oral bioavailability (F = 39%). The significant solubility increase appears linked to the improved oral bioavailability.

UI MeSH Term Description Entries
D008457 Measles A highly contagious infectious disease caused by MORBILLIVIRUS, common among children but also seen in the nonimmune of any age, in which the virus enters the respiratory tract via droplet nuclei and multiplies in the epithelial cells, spreading throughout the MONONUCLEAR PHAGOCYTE SYSTEM. Rubeola
D008459 Measles virus The type species of MORBILLIVIRUS and the cause of the highly infectious human disease MEASLES, which affects mostly children. Edmonston virus
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012324 RNA-Dependent RNA Polymerase An enzyme that catalyses RNA-template-directed extension of the 3'- end of an RNA strand by one nucleotide at a time, and can initiate a chain de novo. (Enzyme Nomenclature, 1992, p293) Nucleoside-Triphosphate:RNA Nucleotidyltransferase (RNA-directed),RNA Replicase,RNA-Dependent RNA Replicase,RNA-Directed RNA Polymerase,RNA Dependent RNA Polymerase,RNA Dependent RNA Replicase,RNA Directed RNA Polymerase,RNA Polymerase, RNA-Dependent,RNA Polymerase, RNA-Directed,RNA Replicase, RNA-Dependent,Replicase, RNA,Replicase, RNA-Dependent RNA
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats

Related Publications

J Maina Ndungu, and Stefanie A Krumm, and Dan Yan, and Richard F Arrendale, and G Prabhakar Reddy, and Taylor Evers, and Randy Howard, and Michael G Natchus, and Manohar T Saindane, and Dennis C Liotta, and Richard K Plemper, and James P Snyder, and Aiming Sun
Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex activity: Synthesis and in vitro evaluation.
September 2007, Bioorganic & medicinal chemistry letters,
J Maina Ndungu, and Stefanie A Krumm, and Dan Yan, and Richard F Arrendale, and G Prabhakar Reddy, and Taylor Evers, and Randy Howard, and Michael G Natchus, and Manohar T Saindane, and Dennis C Liotta, and Richard K Plemper, and James P Snyder, and Aiming Sun
Potent non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex.
July 2008, Journal of medicinal chemistry,
J Maina Ndungu, and Stefanie A Krumm, and Dan Yan, and Richard F Arrendale, and G Prabhakar Reddy, and Taylor Evers, and Randy Howard, and Michael G Natchus, and Manohar T Saindane, and Dennis C Liotta, and Richard K Plemper, and James P Snyder, and Aiming Sun
Non-nucleoside Inhibitors of Zika Virus RNA-Dependent RNA Polymerase.
October 2020, Journal of virology,
J Maina Ndungu, and Stefanie A Krumm, and Dan Yan, and Richard F Arrendale, and G Prabhakar Reddy, and Taylor Evers, and Randy Howard, and Michael G Natchus, and Manohar T Saindane, and Dennis C Liotta, and Richard K Plemper, and James P Snyder, and Aiming Sun
Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase.
March 2012, Journal of medicinal chemistry,
J Maina Ndungu, and Stefanie A Krumm, and Dan Yan, and Richard F Arrendale, and G Prabhakar Reddy, and Taylor Evers, and Randy Howard, and Michael G Natchus, and Manohar T Saindane, and Dennis C Liotta, and Richard K Plemper, and James P Snyder, and Aiming Sun
New non-nucleoside inhibitors of hepatitis C virus RNA-dependent RNA polymerase.
July 2004, Biochemistry. Biokhimiia,
J Maina Ndungu, and Stefanie A Krumm, and Dan Yan, and Richard F Arrendale, and G Prabhakar Reddy, and Taylor Evers, and Randy Howard, and Michael G Natchus, and Manohar T Saindane, and Dennis C Liotta, and Richard K Plemper, and James P Snyder, and Aiming Sun
Correction to Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase.
April 2017, Journal of medicinal chemistry,
J Maina Ndungu, and Stefanie A Krumm, and Dan Yan, and Richard F Arrendale, and G Prabhakar Reddy, and Taylor Evers, and Randy Howard, and Michael G Natchus, and Manohar T Saindane, and Dennis C Liotta, and Richard K Plemper, and James P Snyder, and Aiming Sun
Non-nucleoside inhibitors of HCV polymerase NS5B. Part 2: Synthesis and structure-activity relationships of benzothiazine-substituted quinolinediones.
July 2009, Bioorganic & medicinal chemistry letters,
J Maina Ndungu, and Stefanie A Krumm, and Dan Yan, and Richard F Arrendale, and G Prabhakar Reddy, and Taylor Evers, and Randy Howard, and Michael G Natchus, and Manohar T Saindane, and Dennis C Liotta, and Richard K Plemper, and James P Snyder, and Aiming Sun
Design, synthesis, and structure-activity relationships of pyridoquinazolinecarboxamides as RNA polymerase I inhibitors.
June 2014, Journal of medicinal chemistry,
J Maina Ndungu, and Stefanie A Krumm, and Dan Yan, and Richard F Arrendale, and G Prabhakar Reddy, and Taylor Evers, and Randy Howard, and Michael G Natchus, and Manohar T Saindane, and Dennis C Liotta, and Richard K Plemper, and James P Snyder, and Aiming Sun
Novel 4-thiazolidinones as non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase.
January 2015, Archiv der Pharmazie,
J Maina Ndungu, and Stefanie A Krumm, and Dan Yan, and Richard F Arrendale, and G Prabhakar Reddy, and Taylor Evers, and Randy Howard, and Michael G Natchus, and Manohar T Saindane, and Dennis C Liotta, and Richard K Plemper, and James P Snyder, and Aiming Sun
Nonnucleoside inhibitor of measles virus RNA-dependent RNA polymerase complex activity.
July 2007, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!